
In zzso phase III trials two zzso zzso growth factor zzso approaches have yielded survival benefit in patients with zzso zzso In one approach, the addition of zzso a zzso zzso to standard chemotherapy improved overall survival in zzso and lung cancer patients and zzso survival in breast cancer zzso In the second approach, zzso zzso zzso zzso that block zzso zzso and other zzso in both zzso and cancer cells, demonstrated survival benefit in gastrointestinal zzso tumor and zzso zzso By contrast, adding zzso to chemotherapy failed to increase survival in patients with previously treated and zzso zzso breast zzso Furthermore, addition of zzso a zzso inhibitor developed as a zzso zzso agent, to chemotherapy did not show a similar benefit in zzso zzso cancer zzso These contrasting responses raise critical questions about how these agents work and how to combine them zzso We zzso three of the many potential mechanisms of action of zzso agents, and also discuss progress relating to the identification of potential zzso for zzso efficacy in zzso 

